Compare IT & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IT | GH |
|---|---|---|
| Founded | 1979 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8B | 14.8B |
| IPO Year | 1993 | 2018 |
| Metric | IT | GH |
|---|---|---|
| Price | $156.60 | $100.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 21 |
| Target Price | ★ $270.44 | $102.81 |
| AVG Volume (30 Days) | 1.7M | ★ 2.1M |
| Earning Date | 02-03-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 11.49 | N/A |
| Revenue | ★ $6,459,775,000.00 | $902,569,000.00 |
| Revenue This Year | $6.73 | $35.23 |
| Revenue Next Year | $3.29 | $27.38 |
| P/E Ratio | $13.60 | ★ N/A |
| Revenue Growth | 5.24 | ★ 30.38 |
| 52 Week Low | $139.18 | $34.88 |
| 52 Week High | $544.93 | $120.74 |
| Indicator | IT | GH |
|---|---|---|
| Relative Strength Index (RSI) | 17.05 | 38.60 |
| Support Level | $139.18 | $97.88 |
| Resistance Level | $239.25 | $118.00 |
| Average True Range (ATR) | 9.53 | 5.67 |
| MACD | -8.78 | -1.94 |
| Stochastic Oscillator | 13.29 | 11.61 |
Gartner Inc provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services. The company operates through three business segments, namely Research, Conferences and Consulting. The company generates majority of the revenue from Research segment.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.